KB-1087

Iladatuzumab

Home » Antibody » Iladatuzumab

Background

CD79B is a cell-surface antigen expressed on mature B cells but absent on plasma cells. A majority of mature malignancies of B-cell origin, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia, express CD79B and demonstrate rapid internalization of anti-CD79B antibodies. Iladatuzumab (MCDS0593A) is a humanized IgG1 monoclonal antibody against human CD79B. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin, which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.

Specifications

Catalog Number:
KB-1087
Cell Line Name:
Iladatuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD79b
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.Alex F Herrera, et al. Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. 2.Louise Conilh, et al. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023 Jan 17;16(1):3.
Please enable JavaScript in your browser to complete this form.